BACKGROUND: Cytomegalovirus (CMV) is associated with ischemic heart disease (IHD) among organ transplant recipients. The relationship between the levels of antibody for CMV with IHD in immunocompetent individuals is uncertain. METHODS: We measured baseline CMV immunoglobulin G (IgG) levels in 12,574 participants without IHD from the population-based EPIC-Norfolk cohort, aged 40-70 years old at recruitment in 1993-1997. Underlying causes of death or hospitalization until 31 March 2008 were abstracted from death certificates and a database of hospital admissions, respectively. RESULTS: Of the participants, 58% were seropositive for CMV. After a mean follow-up of 12 years (standard deviation, 2.2 years), 1356 first-time IHD events occurred. After adjustment for classic IHD risk factors, belonging to the highest antibody group was associated with an increased risk of incident IHD, compared with seronegativity (hazard ratio, 1.22; 95% confidence interval, 1.05-1.42). After additional adjustment for measures of social class, inflammation, and possible confounders, this association was unchanged (hazard ratio, 1.21; 95% confidence interval, 1.04-11.41). CONCLUSIONS: This is the first population study to show that CMV IgG antibody levels are related to incident IHD compared to seronegativity. Studies correlating CMV antibody levels with direct measurements of active infection will be necessary.
BACKGROUND: Cytomegalovirus (CMV) is associated with ischemic heart disease (IHD) among organ transplant recipients. The relationship between the levels of antibody for CMV with IHD in immunocompetent individuals is uncertain. METHODS: We measured baseline CMV immunoglobulin G (IgG) levels in 12,574 participants without IHD from the population-based EPIC-Norfolk cohort, aged 40-70 years old at recruitment in 1993-1997. Underlying causes of death or hospitalization until 31 March 2008 were abstracted from death certificates and a database of hospital admissions, respectively. RESULTS: Of the participants, 58% were seropositive for CMV. After a mean follow-up of 12 years (standard deviation, 2.2 years), 1356 first-time IHD events occurred. After adjustment for classic IHD risk factors, belonging to the highest antibody group was associated with an increased risk of incident IHD, compared with seronegativity (hazard ratio, 1.22; 95% confidence interval, 1.05-1.42). After additional adjustment for measures of social class, inflammation, and possible confounders, this association was unchanged (hazard ratio, 1.21; 95% confidence interval, 1.04-11.41). CONCLUSIONS: This is the first population study to show that CMV IgG antibody levels are related to incident IHD compared to seronegativity. Studies correlating CMV antibody levels with direct measurements of active infection will be necessary.
Authors: Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin Journal: Vaccine Date: 2013-10-13 Impact factor: 3.641
Authors: Eshan U Patel; Sara Gianella; Kevin Newell; Aaron A R Tobian; Allison R Kirkpatrick; Fredrick Nalugoda; Mary K Grabowski; Ronald H Gray; David Serwadda; Thomas C Quinn; Andrew D Redd; Steven J Reynolds Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Sara Gianella; Sheldon R Morris; Erick Tatro; Milenka V Vargas; Richard H Haubrich; Eric S Daar; Michael P Dube; Douglas D Richman; Susan J Little; Davey M Smith Journal: J Infect Dis Date: 2013-08-20 Impact factor: 5.226
Authors: Jerrald L Rector; G Neil Thomas; Victoria E Burns; Jennifer B Dowd; Raphael M Herr; Paul A Moss; Marc N Jarczok; Kristina Hoffman; Joachim E Fischer; Jos A Bosch Journal: Diabetologia Date: 2015-08-20 Impact factor: 10.122
Authors: Sarah E Jackson; Anke Redeker; Ramon Arens; Debbie van Baarle; Sara P H van den Berg; Chris A Benedict; Luka Čičin-Šain; Ann B Hill; Mark R Wills Journal: Geroscience Date: 2017-06-24 Impact factor: 7.713